Combined potassium and calcium channel blocking activities as a basis for antiarrhythmic efficacy with low proarrhythmic risk: Experimental profile of BRL-32872

Journal of Pharmacology and Experimental Therapeutics

Volumn 276, Issue 2, 1996, Pages 637-646

  Bril, Antoine ^a   Gout, Bernard ^a   Bonhomme, Mireille ^a   Landais, Laurent ^a   Faivre, Jean François ^a   Linee, Philippe ^a   Poyser, Robert H ^a   Ruffolo Jr , Robert R ^a  

^a SmithKline Beecham Laboratoires P   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; BENZAMIDE DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; N (3,4 DIMETHOXYPHENYL) N [3 [N [2 (3,4 DIMETHOXYPHENYL)ETHYL] N METHYLAMINO]PROPYL] 4 NITROBENZAMIDE; POTASSIUM CHANNEL BLOCKING AGENT;

ANIMAL; ARTICLE; DOG; DRUG EFFECT; ELECTROENCEPHALOGRAPHY; ELECTROSTIMULATION; FEMALE; HEART INFARCTION; HEMODYNAMICS; MALE; PATHOPHYSIOLOGY; RABBIT; TORSADE DES POINTES;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; BENZAMIDES; CALCIUM CHANNEL BLOCKERS; DOGS; ELECTRIC STIMULATION; ELECTROENCEPHALOGRAPHY; FEMALE; HEMODYNAMIC PROCESSES; MALE; MYOCARDIAL INFARCTION; POTASSIUM CHANNEL BLOCKERS; RABBITS; TORSADES DE POINTES;

EID: 0030075361     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. BASHIR, Y., THOMSEN, P. E. B., MOLLER, M., WONG, C., KINGMA, J H., RASMUSSEN, H. S. AND CAMM, A. J.: The efficacy and safety of dofetilide, a novel class III antiarrhythmic agent, in patients with sustained monomorphic ventricular tachycardia (VT) (Abstract). Pac. Clin. Electrophys. 15: 593, 1992.
2. BAZETT, H. C.: An analysis of the time-relations of electrocardiograms. Heart 7: 353-370, 1920.
3. BLACK, S. C., CHI, L., MU, D. X. AND LUCCHESI, B. R.: The antifibrillatory actions of UK-68,798, a class III antiarrhythmic agent. J. Pharmacol. Exp. Ther. 258: 416-423, 1991.
4. BRIL, A., FAIVRE, J F., LANDAIS, L., FOREST, M. C., GOUT, B., LINEE, P., RUFFOLO, JR., R. R. AND POYSER, R. H.: Effect of BRL-32872, a new class III antiarrhythmic agent, on the susceptibility to experimentally-induced triggered arrhythmias (Abstract). FASEB J. 8: A79, 1994a.
5. BRIL, A., GOUT, B., BONHOMME, M., LANDAIS, L., LINEE, P., RUFFOLO, J. R. R. R. AND POYSER, R. H.: BRL-32872, a novel antiarrhythmic agent with potassium and calcium channel antagonistic properties, prevents ventricular fibrillation without inducing torsades de pointes (Abstract). Can J. Physiol. Pharmacol. 72: suppl. 1, 79, 1994b.
6. BRIL, A., FAIVRE, J. F., FOREST, M. C., CHEVAL, B., GOUT, B., LINEE, P., RUFFOLO, J. R. R R. AND POYSER, R. H.: Electrophysiological effect of BRL 32872, a novel antiarrhythmic agent with potassium and calcium channel blocking properties, in guinea-pig cardiac isolated preparations. J. Pharmacol. Exp. Ther. 273: 1264-1272, 1995
7. C.A.S.T. INVESTIGATORS., Preliminary report: Effect of encainide and flecainide on mortality in a ramdomized trial of arrhythmia suppression after myocardial infarction. N. Engl. J. Med 321: 406-412, 1989.
8. CARLSSON, L., ALMGREN, O. AND DUKER, G.: QTU-prolongation and torsades de pointes induced by putative class III antiarrhythmic agents in the rabbit: Etiology and interventions. J. Cardiovase. Pharmacol. 16: 276-285, 1990.
9. CARLSSON, L., ABRAHAMSSON, C., DREWS, L. AND DUKER, G.: Antiarrhythmic effects of potassium channel openers in rhythm abnormalities related to delayed repolarization. Circulation 85: 1491-1500, 1992.
10. + current in cardiac myocytes by dofetilide. J. Pharmacol. Exp. Ther. 262: 809-817, 1992.
11. CHI, L., MU, D. X , DRISCOLL, E. M. AND LUCCHESI, B. R.: Antiarrhythmic and electrophysiologic actions of CK-3579 and sematilide in a conscious canine model of sudden coronary death. J. Cardiovasc. Pharmacol. 16: 312-324, 1990.
12. COBBE, S. M.: Sotalol. In Antiarrhythmic Drugs, ed. by E. M. Vaughan Williams and T. J. Campbell, pp. 365-387, Springer, Berlin, 1989
13. COLATSKY, T. J., FOLLMER, C H. AND STARMER, C. F.: Channel specificity in antiarrhythmic drug action Mechanism of potassium channel block and its role in suppressing and aggravating cardiac arrhythmias. Circulation 82: 2235-2242, 1990.
14. EL-SHERIF, N., ZEILER, R. H., CRAELIUS, W , GOUGH, W. B. AND HENKIN, R.: QTU prolongation and polymorphic ventricular tachyarrhythmias due to bradycardia-dependent early afterdepolarizations Afterdepolarizations and ventricular arrhythmias. Circ. Res. 63: 286-305, 1988.
15. GOUT, B , BONHOMME, M. AND BRIL, A.: Beneficial effect of BRL-32872, a novel antiarrhythmic agent with potassium and calcium blocking action, in dogs with myocardial ischemia (Abstract). J. Mol. Cell. Cardiol. 26: LVIII, 1994.
16. GOUT, B., NICHOLS, A. J., FEUERSTEIN, G. Z. AND BRIL, A.: Antifibrillatory effects of BRL-32872 in anesthetized Yucatan minipigs with regional ischemia. J. Cardiovasc. Pharmacol. 26: 636-644, 1995.
17. GWILT, M., ARROWSMITH, J. E., BLACKBURN, K. J., BURGES, R. A., CROSS, P. E., DALRYMPLE, H. W. AND HIGGINS, A. J.: UK-68,798: A novel, potent and highly selective class III antiarrhythmic agent which blocks potassium channels in cardiac cells J. Pharmacol Exp. Ther. 256: 318-324, 1991.
18. JACKMAN, W. M., SZABO, B., FRIDAY, K. J., MARGOLIS, P. D., MOULTON, K., WANG, X., PATTERSON, E. AND LAZZARA, R.: Ventricular tachyarrhytnmias related to early afterdepolarizations and triggered firing: relationship to QT interval prolongation and potential therapeutic role for calcium channel blocking agents. J. Cardiovasc. Electrophysiol. 1: 170-195, 1990.
19. KATOH, H., NOMOTO, K. I. AND SAWADA, K., Combined effects of class III antiarrhythmic agent E-4031 and verapamil on ventricular arrhythmias induced by 24 hours coronary artery ligation (Abstract). J. Mol. Cell. Cardiol. 22: S70, 1990a.
20. KATOH, H., OGAWA, S., FURUNO, I., SATO, Y., YOH, S., SAEKI, K. AND NAKAMURA, Y.: Electrophysiologic effects of E-4031, a class III antiarrhythmic agent, on re-entrant ventricular arrhythmias in a canine 7-day-old myocardial infarction model. J. Pharmacol. Exp. Ther. 253: 1077-1082, 1990b.
21. KATRITSIS, D. AND CAMM, A. J.: New class III antiarrhythmic drugs. Eur. Heart J. 14: suppl. H, 93-99, 1993.
22. KOERNER, J. E. AND DAGE, R. C.: Antiarrhythmic and electrophysiologic effects of MDL 11,939, a novel class III antiarrhythmic agent in anesthetized dogs. J. Cardiovasc. Pharmacol. 16: 383-393, 1990.
23. KREJCY, K., KRUMPL, G., TODT, H. AND RABERGER, G.: Efficacy of verapamil against ventricular arrhythmias induced by programmed electrical stimulation in the late myocardial infarction phase in dogs. J. Pharm. Pharmacol. 44: 349-354, 1992.
24. LUDBROOK J.: Repeated measurements and multiple comparisons in cardiovascular research. Cardiovasc. Res. 28: 303-311, 1994.
25. LYNCH, J. J , JR., SANGUINETTI, M. C., KIMURA, S. AND BASSETT, A. L.: Therapeutic potential of modulating potassium currents in the diseased myocardium. FASEB J. 6: 2952-2900, 1992.
26. LYNCH, J. J., JR., WALLACE, A. A., STUPIENSKI, R. F. I., BASKIN, E. P., BEAR, C. M., APPLEBY, S. D., SALATA, J. J., JURKIEWICZ, N. K., SANGUINETTI, M. C., STEIN, R. B., GEHRET, J. R., KOTHSTEIN, T., CLAREMON, D. A., ELLIOTT, J. M., BUTCHER, J. W., REMY, D. C. AND BALDWIN, J. J.: Cardiac electrophysiologic and antiarrhythmic actions of two long-acting spirobenzopyran piperidine class III agents, L-702, 958 and L-706,000 [MK-499]. J. Pharmacol. Exp. Ther. 269: 541-554, 1994.
27. + current. Differential sensitivity to block by class III antiarrhythmic agents. J. Gen. Physiol. 96: 195-215, 1990.
28. SINGH, B. N.: Control of cardiac arrhythmias by prolonging repolarization: historical development of the concept and emerging perspectives. In Electropharmacological Control of Cardiac Arrhythmias. To Delay Conduction or to Prolong Refractoriness? ed. by B. N. Singh, H. J. J. Wellens and M. Hiraoka, pp. 427-440, Futura Publishing Company, Inc., Mount Kisco, New York, 1994a.
29. SINGH, B. N.: Amiodarone: Pharmacological, electrophysiological, and clinical profile of an unusual antiarrhythmic compound. In Electropharmacological Control of Cardiac Arrhythmias. To Delay Conduction or to Prolong Refractoriness? ed. by B. N. Singh, H. J. J. Wellens and M. Hiraoka, pp. 497-522, Futura Publishing Company, Inc., Mount Kisco, New York, 1994b.
30. SINGH, B. N.: Whither antiarrhythmic drugs? In Electropharmacological Control of Cardiac Arrhythmias. To Delay Conduction or to Prolong Refractoriness? ed. by B. N. Singh, H. J. J. Wellens and M. Hiraoka, pp. 713-731, Futura Publishing Company, Inc., Mount Kisco, New York, 1994c.
31. UPRICHARD, A. C. G. AND LUCCHESI, B. R.: The efficacy of antiarrhythmic drugs as antifibrillatory agents. In Electropharmacological Control of Cardiac Arrhythmias. To Delay Conduction or to Prolong Refractoriness? ed. by B. N. Singh, H J. J. Wellens and M. Hiraoka, pp. 291-312, Futura Publishing Company, Inc., Mount Kisco, New York, 1994.
32. WALEFFE, A., NZAYINAMBAHO, K., RODRIGUEZ, L M., DEHARENG, A. AND KULBERTUS, H. E.: Mechanisms of termination of supraventricular tachycardias by intravenous class III antiarrhythmic agents. A comparison of amiodarone and sotalol. Eur. Heart J. 10: 1084-1089, 1989.
33. WEISSENBURGER, J., DAVY, J. M., CHEZALVIEL, F., ERTZBISCHOFF, O., POIRIER, J. M., ENGEL, F., LAINEE, P., PENIN, E., MOTTE, G. AND CHEYMOL, G.: Arrhythniogenic activities of antiarrhythmic drugs in conscious hypokalemic dogs with atri-oventricular block: Comparison between quinidine, lidocaine, flecainide, propranolol and sotalol. J. Pharmacol. Exp. Ther. 259: 871-883, 1991.
34. WIESFELD, A. C. P., CRIJNS, H. J G. M., BERGSTRAND, R. H., ALMGREN, O , HILLEGE, H. L. AND LIE, K. L., Torsades de pointes with almokalant, a new class III antiarrhythmic drug. Am. Heart J. 126: 1008-1011, 1993.
35. WIT, A. L. AND JANSE, M. J.: The Ventricular Arrhythmias of Ischemia and Infarction: Electrophysiological Mechanisms, pp. 1-648, Futura Publishing Company, Inc., Mount Kisco, New York, 1993.
36. WONG, W., PAVLOU, H. N., BIRGERSDOTTER-GREEN, U., HILLEMAN, D. E., MOHTUDDIN, S. M. AND RODEN, D. M.: Pharmacology of the class III antiarrhythmic agent sematilide in patients with arrhythmias. Am. J. Cardiol. 69: 206-212, 1992.
37. ZUANETTI, G. AND CORR, P. B.: Antiarrhythmic efficacy of a new class III agent, UK-68,798, during chronic myocardial infarction: Evaluation using three-dimensional mapping. J. Pharmacol. Exp. Ther. 256: 325-334, 1991.